Nanobiotix S.A.
NBTXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Nanobiotix S.A. (NBTX) is listed under Biotechnology. With a market capitalization of $1.92B, it sits in small-cap territory. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer.
Market Cap
$1.92B
Beta
0.56
P/E (TTM)
—
P/E (Fwd)
488.34
EPS (TTM)
$-0.57
EPS (Fwd)
$0.08
ROE
—
ROA
-10.1%
Cash
$52.8M
Total Debt
$95.3M
Free CF
-$7.9M
52W Change
613.0%
Annual Financials
Cash vs Debt
Nanobiotix S.A. carries $95.3M in total debt against $52.8M in cash reserves — debt is roughly 1.8x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow is running at -$7.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time.
NBTX's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Nanobiotix S.A. and its sector.